Showing results (1361-1370 of 1,430) with videos related to

Sort By:
Pageof 143
Theranostics|July 26, 2017
Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-upRui You, Yi-Jun Hua, You-Ping Liu, et al.
International Journal of Cancer|June 4, 2017
Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinomaRui You, Rui Sun, Yi-Jun Hua, et al.
Journal of Cancer|April 21, 2018
Patterns of Failure and Survival Trends Of 720 Patients with Stage I Nasopharyngeal Carcinoma Diagnosed from 1990-2012: A Large-scale Retrospective Cohort StudyLin-Quan Tang, Tong-Yu Lu, Yang Li, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 13, 2019
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy responseSai-Lan Liu, Xue-Song Sun, Jin-Jie Yan, et al.
Cancer Research and Treatment|July 15, 2017
Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective StudyQiu-Yan Chen, Qing-Nan Tang, Lin-Quan Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2017
The <i>RARS-MAD1L1</i> Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal CarcinomaQian Zhong, Zhi-Hua Liu, Zhi-Rui Lin, et al.
Cancer Letters|February 22, 2023
Retraction notice to "Endogenous production of C-C motif chemokine ligand 2 by nasopharyngeal carcinoma cells drives radioresistance-associated metastasis" [Canc. Lett. 468 (2020) 27-40]Shan-Shan Guo, Rui Liu, Yue-Feng Wen, et al.
Cancer Letters|October 12, 2019
RETRACTED: Endogenous production of C-C motif chemokine ligand 2 by nasopharyngeal carcinoma cells drives radioresistance-associated metastasisShan-Shan Guo, Rui Liu, Yue-Feng Wen, et al.
Cancer Communications (London, England)|November 2, 2018
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation StudyQiuyan Chen, Linquan Tang, Na Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|August 4, 2023
A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patientsYu-Jing Liang, Qiu-Yan Chen, Jing-Xiao Xu, et al.
Pageof 143